Cost-Effectiveness of Comprehensive Genomic Profiling in Patients With Non–Small Cell Lung Cancer for the Colombian Health System

•The use of comprehensive genomic profiling (CGP) and target therapies is associated with a substantial improvement in clinical outcomes of patients with advanced non–small cell lung cancer. However, the need to screen a large number of patients to select very few candidates to receive current target therapies raise important concerns about the cost-effectiveness of CGP.•CGP is associated with improvements in length and quality of life of patients with non–small cell lung cancer with an incremental cost-effectiveness ratio below the willingness-to-pay threshold adopted by the Colombian regulatory authorities. These results suggest that CGP is therefore cost-effective from the perspective of the Colombian Health System. These results are robust to the variability and uncertainty of the input parameters but remain sensitive to changes in the price of CGP.•This study provides valuable information to regulatory authorities and other stakeholders about the cost-effectiveness of including CGP in the health benefits package in Colombia. However, given the current costs of CGP, future studies should assess the impact of having CGP on health budgets across the country.